Amgen is trading at $466.44, up 3.23%, amid a reported defensive shift toward healthcare as investors move away from AI-linked stocks; this is sector context, not a confirmed company-specific catalyst.
- Broader indexes were lower, with the Nasdaq down 1.44%, while Amgen rose.
- Amgen’s third-quarter results are scheduled for November 3; no earnings results were reported on October 29.